ArticleInvestigative ophthalmology & visual science2025
The miR-320a/PRDX3 Axis Alleviates the Oxidative Stress and Fibrotic Alterations in Fibroblasts in Thyroid Eye Disease.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Co-g-CJournal of fluorescence · 2026Article
- Hypoxia-Induced Ferroptosis Resistance Drives Orbital Fibrosis in Thyroid Eye Disease.Investigative ophthalmology & visual science · 2026Article
- MicroRNAs in thyroid eye disease: expression signatures and clinical implications.Frontiers in immunology · 2026Review
- Epigenetic Mechanisms in Autoimmune Thyroid Diseases: Bridging Research and Clinical Applications.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Thyroid eye disease (TED) is an autoimmune condition of the orbit characterized by significant morbidity. MicroRNAs (miRNAs) have been identified as key modulators of immune responses and fibrotic processes, with miR-320a emerging as a potential modulator in TED pathogenesis. Methods: This study investigated miR-320a's role in TED by analyzing its expression in TED tissues and assessing the impact of its inhibition on fibroblast activation, fibrosis, and oxidative stress. Peroxiredoxin 3 (PRDX3) was identified as a direct target of miR-320a, and its functional consequences were evaluated. In vivo experiments were also conducted to validate the findings. Results: Inhibition of miR-320a reduced fibroblast activation, fibrosis, and oxidative stress markers. PRDX3 knockdown amplified these effects, indicating its importance in miR-320a-mediated pathways. Overexpression of miR-320a further promoted fibroblast activation, as evidenced by decreased cell viability, DNA synthesis, and the expression levels of fibrotic markers. PRDX3 overexpression could also notably eliminate the effects of miR-320a overexpression. In vivo targeting of the miR-320a/PRDX3 axis reduced oxidative stress and fibrosis in TED models. Conclusions: The study highlights the critical role of miR-320a in TED pathogenesis through its regulation of orbital fibroblast (OF) activation, fibrosis, oxidative stress, and the p38 mitogen-activated protein kinase (p38 MAPK) signaling pathway, mediated by its interaction with PRDX3. Targeting the miR-320a/PRDX3 axis represents a promising therapeutic strategy to alleviate the oxidative stress and fibrotic alterations in TED, underscoring the potential of miR-320a as a therapeutic target in managing TED progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.